TEMECULA, CA -- (MARKET WIRE) -- 10/18/2006 -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund, today announced that portfolio investment Zonda, Incorporated is scheduled to exhibit its products at MEDICA, billed as the world's largest medical trade fair, which is being held from November 15-18, 2006 in Dusseldorf, Germany. Zonda's booth will be in the U.S. Pavilion located in Building 3 at the Messe Dusseldorf Exhibition Center.

The MEDICA trade fair, titled the 38th World Forum for Medicine (www.medica.de ), is expected to feature over 4200 exhibitors from 67 countries around the world showing the latest in medical products and medical-technical devices and systems. Over 137,000 visitors attended the 2005 MEDICA World Forum for Medicine, where Zonda exhibited its HandiLab line of medical diagnostic tests, and the Congress is expected to host a larger number of visitors this year.

Zonda's HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use, which signifies that it complies with the relevant health, safety, environmental protection requirements in Europe and can therefore be legally placed on the market. Zonda's gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use.

"We are pleased to again be exhibiting our HandiLab products at the MEDICA event in Germany, especially considering how effective our marketing efforts in Europe have been over the past year," stated Laurie J. Oleksiewicz, president of Zonda Incorporated. "Included in our presence at MEDICA will be meetings with our major European distributors and other key business contacts who will be in attendance. This is truly a major worldwide medical industry event, and Zonda will use its exhibit to expand the profile of its HandiLab products to a broad industry audience."

MEDICA's exhibit range includes electromedical equipment, medical technology, laboratory equipment, rescue and emergency equipment, diagnostics, drugs, physiotherapy, orthopedic technology, single-use products and consumer goods.

The MEDICA Congress also includes a total of approximately 200 certified seminars and training courses -- a recognized platform for the presentation of the latest scientific findings and a forum for knowledge transfer so as to put theory into medical practice. The Congress lectures range from prevention to rehabilitation, from homeopathic methods to high-tech medicine, from state-of-the-art diagnostics to targeted therapies. 2006 will see the following focal themes: cardiology, gastroenterology, oncology, metabolic disorders, infectiology and imaging processes as well as neurological topics including polyneuropathies, depression and dementia disorders.

"Zonda is again placing itself at the center of the medical supply world through its attendance at the MEDICA Congress, and we are confident that as a result, the value of our investment in this company will continue to grow," stated Robert McCoy, chairman and chief executive officer of CLX Investment Company.

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.asp.

About Zonda, Incorporated

Zonda, Inc. (www.zondaincusa.com), in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company (www.clxinvestments.com) holds a 31% equity interest in Zonda, Inc. (www.zondaincusa.com). CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.